Clinical Trial Update: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This document reports the Phase 2 results for sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors, focusing on efficacy and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumors

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Pancreatic Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2012-08-27